IL151627A0 - Divided dose therapies with vascular damaging activity - Google Patents

Divided dose therapies with vascular damaging activity

Info

Publication number
IL151627A0
IL151627A0 IL15162701A IL15162701A IL151627A0 IL 151627 A0 IL151627 A0 IL 151627A0 IL 15162701 A IL15162701 A IL 15162701A IL 15162701 A IL15162701 A IL 15162701A IL 151627 A0 IL151627 A0 IL 151627A0
Authority
IL
Israel
Prior art keywords
vascular damaging
divided dose
damaging activity
dose therapies
damaging agent
Prior art date
Application number
IL15162701A
Other languages
English (en)
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of IL151627A0 publication Critical patent/IL151627A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL15162701A 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity IL151627A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (1)

Publication Number Publication Date
IL151627A0 true IL151627A0 (en) 2003-04-10

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15162701A IL151627A0 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Country Status (23)

Country Link
US (1) US20030055024A1 (zh)
EP (1) EP1272200B1 (zh)
JP (1) JP2003528921A (zh)
KR (1) KR20020084267A (zh)
CN (1) CN1422157A (zh)
AT (1) ATE298240T1 (zh)
AU (2) AU2001242586B2 (zh)
BR (1) BR0109671A (zh)
CA (1) CA2402078A1 (zh)
CZ (1) CZ20023231A3 (zh)
DE (1) DE60111622T2 (zh)
EE (1) EE200200549A (zh)
ES (1) ES2243466T3 (zh)
HU (1) HUP0300576A3 (zh)
IL (1) IL151627A0 (zh)
IS (1) IS6555A (zh)
MX (1) MXPA02009603A (zh)
NO (1) NO20024683L (zh)
NZ (1) NZ534190A (zh)
PL (1) PL357282A1 (zh)
PT (1) PT1272200E (zh)
SK (1) SK13902002A3 (zh)
WO (1) WO2001074369A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
CA2529409A1 (en) * 2003-06-18 2004-12-29 Angiogene Pharmaceuticals Limited Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI830078L (fi) * 1982-01-15 1983-07-16 Lilly Co Eli Askorbinsyraetrar och liknande foereningar
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
WO1991015495A1 (en) * 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
EP0586608A1 (en) * 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
DE60027719T2 (de) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. Krebstherapie
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
CN1422157A (zh) 2003-06-04
KR20020084267A (ko) 2002-11-04
AU2001242586B2 (en) 2004-12-16
PL357282A1 (en) 2004-07-26
SK13902002A3 (sk) 2003-05-02
US20030055024A1 (en) 2003-03-20
HUP0300576A3 (en) 2005-02-28
NZ534190A (en) 2007-05-31
EP1272200A1 (en) 2003-01-08
ES2243466T3 (es) 2005-12-01
IS6555A (is) 2002-10-18
JP2003528921A (ja) 2003-09-30
WO2001074369A1 (en) 2001-10-11
EE200200549A (et) 2004-02-16
EP1272200B1 (en) 2005-06-22
CA2402078A1 (en) 2001-10-11
PT1272200E (pt) 2005-09-30
NO20024683L (no) 2002-10-15
ATE298240T1 (de) 2005-07-15
DE60111622D1 (de) 2005-07-28
DE60111622T2 (de) 2006-05-18
BR0109671A (pt) 2003-02-04
CZ20023231A3 (cs) 2003-01-15
AU4258601A (en) 2001-10-15
MXPA02009603A (es) 2004-05-14
NO20024683D0 (no) 2002-09-30
HUP0300576A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
ZA200107920B (en) Apomorphine and sildenafil composition.
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
AU4258101A (en) Combination therapies with vascular damaging activity
HK1130422A1 (zh) 去鐵酮的新用途
IL155781A0 (en) Effective antitumor treatments
NZ507203A (en) Use of dexmedetomidine for ICU sedation
GB0130677D0 (en) Medicaments and novel compounds
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
AU4258601A (en) Divided dose therapies with vascular damaging activity
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
IL159770A0 (en) Calcium salts with cytotoxic activity
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
IL164092A0 (en) The use of devazepide as analgesic agent
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
GB0223379D0 (en) Combination therapy